Cardiff Lexington Corp (CDIX) presents deeply negative recovery to equity under a liquidation lens as of December 31, 2025. MFFAIS reports a cash liquidation value of approximately -$25.2M and a liquid liquidation value of approximately -$3.2M, confirming that common equity has zero recovery in any plausible wind-down scenario. Total reported assets are $29.1M against total liabilities of $26.0M, yielding book equity of -$2.5M (stockholders' deficit). However, the asset base is heavily impaired on a liquidation basis: the dominant asset is accounts receivable of $22.1M (net of $400K allowance), representing personal-injury-related healthcare claims recoverable at a settlement realization rate that the company itself has marked down from 49% to 42-44% of gross billings. Under the 90-95% haircut applicable to trade AR, and given the illiquid, litigation-contingent nature of these claims, actual recovery is likely closer to 50-60% of carrying value — a $9-11M impairment on this line alone. Goodwill of $5.7M receives a 100% haircut, PP&E net is $3K (already effectively zero), and the real estate land parcel (Edge View) at $540K carries book value that may approximate liquidation value given its undeveloped Idaho acreage. The liability stack is dominated by the DML revolving receivable line of credit at $17.2M (current, maturing September 2026), plus accrued interest of $673K. Notes and loans payable total $18.4M current. Convertible notes add $118K. Operating lease obligations are $221.5K. Critically, accrued related-party compensation for the CEO and former Chairman totaled approximately $4.4M at year-end, though subsequent events disclose conversion of $2.37M (CEO) and $2.35M (former Chairman) into common stock in January and March 2026, respectively — partially reducing this liability post-period. Preferred stock in mezzanine equity totals $5.5M (series N and X), which sits ahead of common equity in liquidation. Cumulative accrued preferred dividends on series X ($437K) and series Y ($408K) represent additional obligations not fully captured in the headline liability figure. The DML facility is secured by Nova's accounts receivable; in a liquidation, DML would have first claim on those AR collections, materially impairing any residual for unsecured creditors or preferred holders. Year-end cash was $318K, down $870K from the prior year-end ($1.19M). The company generated $11.5M in healthcare revenue but incurred $6.8M in interest expense, driven by DML facility fees, resulting in a net loss of $5.5M from continuing operations. NOL carryforwards of $24.4M are fully valuation-allowanced. Series N preferred redemption provisions were removed in January 2026 via certificate amendment, reclassifying $3.8M from mezzanine to permanent equity prospectively — this does not alter the liquidation priority stack but removes the mandatory cash redemption trigger. The filing discusses $6.4M of interest expense on the DML line as a component of cost structure but this is captured in the XBRL interest expense tags. The accrued executive compensation discussed in Note 13 ($4.4M aggregate) is included in accrued expenses — related parties but not separately XBRL-tagged as a distinct line in TAG_CONTEXT.
▼ Community Notes